• Vaccine Ontology ID: VO_0011545
• Type: DNA vaccine
• Status: Research
• Antigen: C. jejuni fibronectin binding protein cadF
• cadF gene engineering:
  • Type: DNA vaccine construction
  • Description: The chitosan-DNA vaccines was prepared by embedding pcDNA3.1(+)-cadF with chitosan (Zheng et al., 2007).
  • Detailed Gene Information: Click Here.
• Vector: pcDNA3.1(+) (Zheng et al., 2007)
• Immunization Route: Intranasal

• Vaccine Ontology ID: VO_0011488
• Type: DNA vaccine
• Status: Research
• Antigen: C. jejuni bifunctional adhesin/ABC transporter aspartate/glutamate-binding protein
• peb1A gene engineering:
  • Type: DNA vaccine construction
  • Description: The chitosan-DNA vaccine was prepared by embedding pcDNA3.1(+)-peblA with chitosan (Zheng et al., 2007).
  • Detailed Gene Information: Click Here.
• Vector: pcDNA3.1(+) (Zheng et al., 2007)
• Immunization Route: Intranasal

• Vaccine Ontology ID: VO_0011495
• Type: Subunit vaccine
• Status: Research
• Antigen: C. jejuni flagellin subunit protein FlaC
• FlaC gene engineering:
  • Type: Recombinant protein preparation
  • Description: The flaC gene from C. jejuni 81-176 was expressed in Escherichia coli as hexahistidine-tagged proteins in pET-19b. Strains of BL21(DE3) containing each clone were grown in Luria broth containing 100 μg/ml ampicillin and proteins were purified by nickel chromatography under native conditions (Baqar et al., 2008).
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0001321
• Immunization Route: Intranasal

• Vaccine Ontology ID: VO_0011485
• Type: Subunit vaccine
• Status: Research
• Antigen: C. jejuni flagellum-secreted protein FspA1
• fspA1 gene engineering:
  • Type: Recombinant protein preparation
  • Description: The fspA1 gene from C. jejuni 81-176 was expressed in Escherichia coli as hexahistidine-tagged proteins in pET-19b. Strains of BL21(DE3) containing each clone were grown in Luria broth containing 100 μg/ml ampicillin and proteins were purified by nickel chromatography under native conditions (Baqar et al., 2008).
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0001321
• Immunization Route: Intranasal

• Vaccine Ontology ID: VO_0011487
• Type: Subunit vaccine
• Status: Research
• Antigen: C. jejuni flagellum-secreted protein FspA2
• fspA2 gene engineering:
  • Type: Recombinant protein preparation
  • Description: The fspA2 gene from C. jejuni CG8486 were expressed in Escherichia coli as hexahistidine-tagged proteins in pET-19b. Strains of BL21(DE3) containing each clone were grown in Luria broth containing 100 μg/ml ampicillin and proteins were purified by nickel chromatography under native conditions (Baqar et al., 2008).
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0001321
• Immunization Route: Intranasal

• Vaccine Ontology ID: VO_0011493
• Type: Subunit vaccine
• Status: Research
• Antigen: C. jejuni structural flagella protein flaA and maltose-binding protein MBP
• FlaA from C. jejuni 81-176 gene engineering:
  • Type: Recombinant protein preparation
  • Description: Purification schemes were essentially as recommended by NEB. DH5α containing the flagellin-MBP fusion was grown overnight in 10 ml of rich medium (10 g of tryptone, 5 g of yeast extract, 5 g of NaCl, and 2 g of glucose/liter) supplemented with 100 μg of ampicillin per ml and used to inoculate a fresh 1-liter culture of the same medium. This culture was grown with shaking at 37°C to an optical density at 600 nm of 0.5, and IPTG (isopropyl-β-d-thiogalactoside; Gibco, Gaithersburg, Md.) was added to a final concentration of 0.3 mM (Lee et al., 1999).
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0001321
  • Description: Mutant E. coli heat-labile enterotoxin (LT(R192G)) (Lee et al., 1999)
• Immunization Route: Intranasal

• Vaccine Ontology ID: VO_0004203
• Type: Subunit vaccine
• Status: Research
• Antigen: Recombinant PorA protein
• PorA gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0001272
• Immunization Route: orally

• Vaccine Ontology ID: VO_0004124
• Type: Recombinant vector vaccine
• Antigen: Campylobacter PEB1 is an adherence factor that is highly immunogenic in humans (Sizemore et al., 2006).
• Preparation: Three live, attenuated deltaphoP/Q Salmonella enteric serovar Typhimurium strains expressing PEB1 minus its signal sequence (PEB1-ss) from three different plasmids were prepared. The three plasmids include a pBR-based asd plasmid, an arabinose-based runaway plasmid, which each expressed PEB1-ss in the bacterial cytosol, and a PEB1::HlyA fusion plasmid that directs secretion of PEB1-ss into the extracellular milieu (Sizemore et al., 2006).
• Virulence: PEB1 is an adherence factor that is highly immunogenic in humans (Sizemore et al., 2006).
• Description: PEB1, the major cell-binding factor of Campylobacter jejuni, is a homolog of the binding component in Gram-negative nutrient transport systems (Prokhorova et al., 2006).

• Vaccine Ontology ID: VO_0004100
• Type: Inactivated or "killed" vaccine
• Antigen: inactivated whole-cell Campylobacter jejuni (CWC)
• Adjuvant:
  • VO ID: VO_0001322
  • Description: 25 mg of a mucosal adjuvant, the heat-labile enterotoxin of Escherichia coli (LT) has been used (Baqar et al., 1995b).
• Preparation: The CWC vaccine is prepared from the 81-176 strain of C. jejuni and consists of a 1:1 mixture of heat (60 C, 60 min)- and formalin (0.02 M)-inactivated Campylobacter whole cells. Each vaccination group receives oral doses of CWC vaccine containing bacterial cells alone or in combination with 25 mg of LT. Just prior to vaccination, gastric acidity is neutralized by 2 doses of a 5% NaHCO3 solution (pH 8.5) with a 15-min interval (Baqar et al., 1995b).
• Virulence: Volunteers given the CWC vaccine have similar IgA-ASC and sIgA responses and in vitro induction of IFN to Campylobacter antigens (Walker, 2005).
• Description: Whole-cell vaccine formulations deserve further evaluation as candidate vaccines and the potential value of mucosal adjuvants, like LT, in enteric vaccine development are not in doubt (Baqar et al., 1995).

• Vaccine Ontology ID: VO_0004101
• Type: Conjugate vaccine
• Antigen: recombinant protein comprising the maltose-binding protein (MBP) of E. coli fused to amino acids 5 to 337 of the FlaA flagellin of Campylobacter coli VC167 (Lee et al., 1999)
• FlaA from C. jejuni NCTC 11168 gene engineering:
  • Type: flagellin protein
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0001321
  • Description: immunization occurs with the mutant E. coli heat-labile enterotoxin (LT( R192G)) as a mucosal adjuvant (Lee et al., 1999)
• Preparation: Part of the flaA gene ( 780 base pairs ) was cloned in plasmid pBEB downstream and in frame with the LT-B to allow expression of a hybrid protein . Transformed E coli chi 6097 expressed the hybrid protein ( 43 kdaltons ) in inclusion bodies at mid log phase . The inclusion bodies were isolated , and the identity of the protein was verified by western blot . (Khoury et al., 1995)
• Virulence: The full range of MBP-FlaA doses were effective in eliciting antigen-specific serum IgG responses, and these responses were enhanced by adjuvant use. Stimulation of FlaA-specific intestinal secretory IgA (sIgA) responses required immunization with higher doses of MBP-FlaA or coadministration of lower doses with the adjuvant (Lee et al., 1999).
• Description: A mucosal vaccine was used in an effort to elicit serum IgG and intestinal secretory IgA. A genetic hybrid of the Campylobacter jejuni flaA gene with LT-B of Escherichia coli and assessment of the efficacy of the hybrid protein has been developed an oral chicken vaccine (Wilkinson et al., 2003).

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: BALB/c mice were intranasally immunized in a four-dose primary series (7 d intervals) at doses of 60 microg chitosan-DNA vaccines each time (Zheng et al., 2007).
• Challenge Protocol: Mice were attacked repeatedly through intragastric administration of C. jejuni HS:19 at the 8th week after the immunization and protective efficacy was determined by detecting the degrees of protection afforded against C. jejuni invaded (Zheng et al., 2007).
• Efficacy: The mice immunized with chitosan-DNA vaccines have generated high levels of IgA and IgG from the sera and IgA from the intestinal secretions and the P/N value went up to 20.58, 30.13 and 6.87 respectively. Moreover the chitosan-DNA vaccines induced strongest level of protection in BALB/c mice against challenge with C. jejuni HS:19 strain and the protective efficacies was 93.70. The results of this study indicate that the chitosan-DNA vaccines could induce significant protective immunity against C. jejuni challenge in the mice model (Zheng et al., 2007).

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: BALB/c mice were intranasally immunized in a four-dose primary series (7 d intervals) at doses of 60 microg chitosan-DNA vaccines each time (Zheng et al., 2007).
• Immune Response: The mice immunized with chitosan-DNA vaccines have generated high levels of IgA and IgG from the sera and IgA from the intestinal secretions and the P/N value went up to 20.58, 30.13 and 6.87, respectively (Zheng et al., 2007).
• Challenge Protocol: Mice were attacked repeatedly through intragastric administration of C. jejuni HS:19 at the 8th week after the immunization and protective efficacy was determined by detecting the degrees of protection afforded against C. jejuni invaded (Zheng et al., 2007).
• Efficacy: The chitosan-DNA vaccines induced strongest level of protection in BALB/c mice against challenge with C. jejuni HS:19 strain and the protective efficacies was 93.70 (Zheng et al., 2007).

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Mice were lightly anesthetized with isoflurane, and 30 μl of phosphate-buffered saline (PBS) alone or PBS containing 5 μg (7 to 10 mice per group) or 25 or 100 μg (10 to 18 mice per group) of protein was applied a drop (5 to 6 μl) at a time to the external nares. A total of three vaccinations for each dose level of each protein were delivered at 2-week intervals. To determine efficacy, animals receiving 100 μg of each protein alone or with 1 μg of LTR192G as the adjuvant were challenged with homologous or heterologous strains of C. jejuni. Following vaccination, animals were observed for two consecutive days for the development of vaccine-associated side effects (Baqar et al., 2008).
• Challenge Protocol: Twenty-eight days following the last vaccination, mice were intranasally challenged with 3 × 10^9 CFU of C. jejuni 81-176 or CG8486 (Baqar et al., 2008).
• Efficacy: FlaC provided an 18% protection against disease from C. jejuni 81-176 (Baqar et al., 2008).

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Mice were lightly anesthetized with isoflurane, and 30 μl of phosphate-buffered saline (PBS) alone or PBS containing 5 μg (7 to 10 mice per group) or 25 or 100 μg (10 to 18 mice per group) of protein was applied a drop (5 to 6 μl) at a time to the external nares. A total of three vaccinations for each dose level of each protein were delivered at 2-week intervals. To determine efficacy, animals receiving 100 μg of each protein alone or with 1 μg of LTR192G as the adjuvant were challenged with homologous or heterologous strains of C. jejuni. Following vaccination, animals were observed for two consecutive days for the development of vaccine-associated side effects (Baqar et al., 2008).
• Challenge Protocol: Twenty-eight days following the last vaccination, mice were intranasally challenged with 3 × 10^9 CFU of C. jejuni 81-176 or CG8486 (Baqar et al., 2008).
• Efficacy: Immunization with FspA1 resulted in 57.8% protection without adjuvant or 63.8% protection with adjuvant against homologous challenge with 81-176 (Baqar et al., 2008).
• Host IgA response
  • Description: FspA1 induced significantly high levels of fecal IgA in mice 7 days after last vaccination. These results are compared to PBS vaccinated mice (Baqar et al., 2008).
  • Detailed Gene Information: Click Here.
• Host IgG response
  • Description: FspA1 induced significantly high levels of serum immunoglobulin G (IgG) in mice 18-20 days after 3rd vaccination. These results are compared to PBS vaccinated mice (Baqar et al., 2008).
  • Detailed Gene Information: Click Here.

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Mice were lightly anesthetized with isoflurane, and 30 μl of phosphate-buffered saline (PBS) alone or PBS containing 5 μg (7 to 10 mice per group) or 25 or 100 μg (10 to 18 mice per group) of protein was applied a drop (5 to 6 μl) at a time to the external nares. A total of three vaccinations for each dose level of each protein were delivered at 2-week intervals. To determine efficacy, animals receiving 100 μg of each protein alone or with 1 μg of LTR192G as the adjuvant were challenged with homologous or heterologous strains of C. jejuni. Following vaccination, animals were observed for two consecutive days for the development of vaccine-associated side effects (Baqar et al., 2008).
• Challenge Protocol: Twenty-eight days following the last vaccination, mice were intranasally challenged with 3 × 10^9 CFU of C. jejuni 81-176 or CG8486 (Baqar et al., 2008).
• Efficacy: Immunization with FspA2 provided 38.4% (without adjuvant) or 47.2% (with adjuvant) protection against disease from homologous challenge with CG8486 (Baqar et al., 2008).

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Mice were anesthetized with methoxyflurane (Metofane; Pitman-Moore, Mundelein, Ill.) and immunized intranasally with 30 to 35 μl of fusion protein by using a micropipette. The doses used were 0, 3, 6, 12, 25, or 50 μg of fusion protein in phosphate-buffered saline (PBS), either alone or in combination with 5 μg of the genetically modified heat-labile enterotoxin of E. coli, designated LTR192G as an adjuvant. A second dose was administered 8 days after the first vaccination (Lee et al., 1999).
• Challenge Protocol: Mice were intranasally challenged with 2 × 10^9 C. jejuni bacteria/mouse 26 days after the second vaccination, and the animals were monitored for sickness and death for 5 days (Lee et al., 1999).
• Efficacy: The protective efficacies of a 50 microgram of MBP-FlaA plus LT(R192G) dose against disease symptoms and intestinal colonization were 81.1 and 84%, respectively. When mice which had been immunized with 50 microgram of MBP-FlaA plus LT(R192G) intranasally were challenged orally with 8 x 10^10, 8 x 10^9, or 8 x 10^8 cells of strain 81-176, the protective efficacies against intestinal colonization at 7 days postinfection were 71.4, 71.4, and 100%, respectively (Lee et al., 1999).
• Host IgA response
  • Description: Stimulation of FlaA-specific intestinal secretory IgA (sIgA) responses required immunization with higher doses of MBP-FlaA (>/=25 microgram) or coadministration of lower doses with the adjuvant. IgA titers were significant 7 days after immunization as compared to PBS-vaccinated mice (Lee et al., 1999).
  • Detailed Gene Information: Click Here.
• Host IgG response
  • Description: The full range of MBP-FlaA doses were effective in eliciting significant antigen-specific serum immunoglobulin G (IgG) responses, and these responses were enhanced by adjuvant use, except in the highest dosing group. The results were compared to PBS vaccinated mice 7 days after immunization (Lee et al., 1999).
  • Detailed Gene Information: Click Here.

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: BALB/c mice were orally vaccinated twice at a weekly interval with the purified GST-PorA fusion protein combined with a modified heat-labile enterotoxin of Escherichia coli toxin, LT R192G, as an adjuvant. Mice immunized with LT R192G or PBS (pH 7.2) alone were included as controls. Vaccination was done by using a stainless steel, curved-ball-tip feeding needle (20 gauge, 1.5-in. long; Popper and Sons, Inc., New Hyde Park, NY). Just prior to vaccination, gastric acidity was neutralized with two doses (0.5 ml each) of a 5% sodium bicarbonate (pH 8.5) solution given as an oral gavage at an interval of 15 min. An amount of 300 µg of the GST-PorA fusion protein mixed with 5 µg of LT R192G in a total volume of 300 µl in PBS (pH 7.2) was given to each of nine animals. Another group of mice was each fed with 5 µg of LT R192G and yet another group each fed with 1x PBS (pH 7.2) (Abimiku et al., 1989; Islam et al., 2010)
• Challenge Protocol: Mice were challenged with bacterial culture 3 weeks after the second vaccine dose, immediately after tail vein blood collection. A 48-h bacterial culture grown on campylobacter agar was suspended in PBS (pH 7.2) to a concentration of 2 x 109 CFU per ml, and 0.5 ml of the suspension was orally fed to the mice immediately after neutralization of the gastric acidity (Islam et al., 2010).
• Efficacy: The vaccine produced robust antibody responses against both antigens in serum and secretion. Since strain C31 was a poor colonizer, homologous protection could not be studied. The protective efficacies of heterologous strains were 43% (for strain 48, P < 0.001), 29% (for strain 75, P < 0.005), and 42% (for strain 111, P < 0.001) for the 9-day period compared to control mice given phosphate-buffered saline (Islam et al., 2010).

Mouse Response

• Host Strain: Female, BALB/c Mouse Specific Pathogen Free (MSP) 7–9 weeks of age from Taconic
• Vaccination Protocol: Mice that had been acclimated for 5 days were vaccinated with freshly prepared inocula on days 1 and 12 of the experiment by pipet feeding. The target concentration for this experiment was 1–2.5E8 in 50 μl (Sizemore et al., 2006).
• Persistence: MGN4735 was able to colonize the intestine to a high level over the entire test period of 9 days post-inoculation while those mice that survived challenge with 81-176 cleared the infection (Sizemore et al., 2006).
• Immune Response: Serum IgG responses specific for PEB1-ss were induced by pBR-derived and runaway plasmids, with 100 and 90% seroconversion, respectively, at a 1:500 dilution of anti-sera as measured by Western blot analysis, while the PEB1-ss::HlyA fusion plasmid induced serum IgG in only 20% of the mice (Sizemore et al., 2006).
• Side Effects: no adverse side effects were observed
• Challenge Protocol: Challenge of vaccinated BALB/c mice was based on the model developed by Baqar et al. (Baqar et al., 1995b). C. jejuni strain 81-176 served as the challenge strain in the oral model (Sizemore et al., 2006).
• Efficacy: Although significant levels of anti-PEB serum IgG were induced, no protection against oral Campylobacter jejuni challenge was observed (Sizemore et al., 2006).
• Description: Three live attenuated ΔphoP/Q Salmonella enteric serovar Typhimurium strains expressing PEB1 minus its signal sequence (PEB1-ss) from three different plasmids: a pBR-based asd plasmid, an arabinose-based runaway plasmid, which each expressed PEB1-ss in the bacterial cytosol, and a PEB1::HlyA fusion plasmid that directs secretion of PEB1-ss into the extracellular milieu are described above (Sizemore et al., 2006).

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Mice were orally immunized in a three-dose primary series with CWC vaccine particles alone or in combination with a mucosal adjuvant, the heat-labile enterotoxin of Escherichia coli (LT) (Baqar et al., 1995b).
• Persistence: Ninety percent of control animals remain colonized for 9 days post-challenge. A similar colonization pattern is observed in mice vaccinated with LT alone. Clearance of challenge organisms from mice receiving CWC vaccine alone appear to be dependent on the amount of vaccine administered. Although 80% of the mice receiving the highest vaccine dose cleared the infection within 3 days of challenge, the remaining 20% were colonized for the remainder of the study period (Baqar et al., 1995b).
• Immune Response: Campylobacter-specific intestinal IgA responses are dependent on the use of LT, whereas IgA and IgG responses in serum are not. Intestinal lavage fluid collected from sham-immunized animals at 7 d post-vaccination have no detectable levels of Campylobacter- or LT-specific secretory IgA (sIgA) or IgG. When CWC is administered over a 10,000-fold range of doses, only 20% of the mice immunized with the low or intermediate doses mount a significant Campylobacter-specific sIgA response. In contrast, administering the same doses with LT resulted in a substantial enhancement of the sIgA response to vaccine-associated Campylobacter antigens in all vaccination groups (Baqar et al., 1995b).
• Side Effects: Both the CWC and CWC-LT vaccine formulations are well tolerated, with no weight loss or signs consistent with toxicity in immunized animals. Histopathological examination of the intestinal mucosa and other organ systems following vaccination fails to detect evidence of tissue damage or severe inflammation (Baqar et al., 1995b).
• Challenge Protocol: At ~4 wks post-vaccination, mice were challenged orally with C. jejuni, and duration of colonization was determined by the monitoring of fecal shedding. Efficacy was determined by measuring the degree of protection afforded against intestinal colonization and systemic dissemination of challenge organisms (Baqar et al., 1995b).
• Efficacy: Colonization resistance was induced over a broad range of vaccine doses when LT was included. However, only the highest dose of CWC alone gave comparable levels of protection. Both formulations provided equivalent protection against systemic spread of challenge organisms. These results indicate that both whole-cell vaccine formulations deserve further evaluation as candidate vaccines and also highlight the potential value of mucosal adjuvants, like LT, in enteric vaccine development (Baqar et al., 1995b).
• Description: Inactivated Campylobacter whole-cell vaccines (CWC) must be given orally in large doses to be effective. Drawbacks could be overcome by the coadministration of LT (Baqar et al., 1995b).

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Mice were immunized intranasally with two doses of 3 to 50 mg of MBP-FlaA, given 8 days apart, with or without 5 mg of the mutant E. coli heat-labile enterotoxin (LTR192G) as a mucosal adjuvant (Lee et al., 1999).
• Persistence: The results showed that, when challenged with bacteria, there was a reduction in colonization as early as 3 days after infection and that no campylobacter organisms could be detected in stools by 7 days post-feeding (Lee et al., 1999).
• Immune Response: Stimulation of FlaA-specific intestinal secretory IgA (sIgA) responses required immunization with higher doses of MBP-FlaA or co-administration of lower doses with the adjuvant (Lee et al., 1999).
• Side Effects: Animals were monitored for sickness and death for 5 days and only minimal adverse side effects were encountered (Lee et al., 1999).
• Challenge Protocol: Mice were intranasally challenged after the second vaccination. Fecal excretion of C. jejuni was monitored daily for 10-14 days after challenge by culturing fecal homogenates. Putative colonies were confirmed by morphology and oxidase reactions. Mice were challenged orally with 0.5 ml of various doses of C. jejuni. Fecal excretion was monitored as described above for 7-9 days (Lee et al., 1999).
• Efficacy: The full range of MBP-FlaA doses were effective in eliciting antigen-specific serum IgG responses, and these responses were enhanced by adjuvant use, except in the highest dosing group. When vaccinated mice were challenged intranasally 26 days after immunization, the best protection was seen in animals given 50 mg of MBP-FlaA plus LTR192G. The protective efficacies of this dose against disease symptoms and intestinal colonization were 81.1 and 84%, respectively. When mice which had been immunized intranasally were challenged orally with 8 x 10^10, 8 x 10^9, or 8 x 10^8 cells of strain 81-176, the protective efficacies against intestinal colonization at 7 days postinfection were 71.4, 71.4, and 100%, respectively (Lee et al., 1999).
• Description: It is interesting that antibodies generated during natural infection by either strain 81-176 or strain VC167 appear to react more strongly to glycosylated flagellins isolated from Campylobacter spp. than to unglycosylated, recombinant flagellins isolated from E. coli. Immunization with the recombinant fusion protein lacking post-translational modifications may lead to antibody production against epitopes which are less immunogenic in the native molecule due to differences in folding and/or masking by the carbohydrate moiety but are, nonetheless, capable of eliciting a protective immune response. Further evaluation of this recombinant flagellin is ongoing as a vaccine in a ferret diarrheal disease model (Lee et al., 1999).

Chicken Response

• Vaccination Protocol: A hybrid protein was administered as a vaccine to chickens either orally or i.m. Alimentary secretions were collected , and specific antibodies were assayed by western blot analyses (Khoury et al., 1995).
• Persistence: Seventy-two percent of the birds vaccinated orally with 1000 micrograms protein showed detectable antibodies against C jejuni flagellin in the excreta . None of the control birds produced detectable antibody to this antigen (Khoury et al., 1995).
• Immune Response: Chickens orally immunized developed serum IgG and mucosal IgA responses against Campylobacter membrane proteins, as measured by an ELISA test. Protection experiments show that chicken immunization greatly reduces the ability of heterologous wild type C jejuni strain to colonize the bird cecum (Wyszynska et al., 2004).
• Side Effects: No adverse side effects have been associated with this vaccine in chickens.
• Challenge Protocol: For trials to demonstrate clearance of Campylobacter, groups of chickens were vaccinated with the hybrid protein at 2 and 4 wk of age and challenged at 3 wk with an excess of Cjejuni. The number of birds that remained colonized at 5 wk of age was significantly lower among the vaccinated birds than among controls (Khoury et al., 1995).
• Efficacy: The nature of the antibody response to MOMP during in vivo infection is not well understood. Antibody responses elicited in Campylobacter-colonized chickens demonstrates that proteoliposomes restore reactivity to rabbit antibodies. Sera from naturally or experimentally infected chickens reacts weakly, suggesting that the chicken antibody response is predominantly directed against conformational epitopes. These observations provide direct evidence for conformation-dependent humoral responses induced by Campylobacter infection, demonstrate that C jejuni is immunogenic in its natural host and suggest that proteoliposomes may be potentially used for the evaluation of vaccines (Huang et al., 2007).
• Description: This is a conserved immunodominant protein in this organism and a promising vaccine candidate because the protein is expressed in multiple Campylobacter isolates from both chicken and human hosts (Martin et al., 1999).

Ferret Response

• Host Strain: Mustela putorius furo
• Vaccination Protocol: Food was withheld prior to challenge. The vaccine dose was administered orally via a pediatric nasogastric tube. After 60 min, animals were administered paragoric i.p. to slow peristalsis. Drinking water was supplemented with tetracycline for three days prior to rechallenge to decrease the competing intestinal microflora (Burr et al., 2005).
• Persistence: An oral regimen delivered on days 0, 3, 5, and 7 provided enhanced protection following oral homologous challenge delivered at Days 0 and 14. The percent protection observed was 100% in previously infected ferrets, 50% in a two-dose CWC group, and 89% in a four-dose CWC group. Protection was afforded through vaccination with sufficient inactivated whole cell vaccine, but protection was obtained regardless of the inclusion of the adjuvant LTR192G (Burr et al., 2005).
• Immune Response: Antibodies generated during natural infection in ferrets by either strain 81-176 or strain VC167 appeared to react more strongly to glycosylated flagellins isolated from Campylobacter spp . than to unglycosylated , recombinant flagellins isolated from E coli . (Lee et al., 1999)
• Side Effects: Following infection, animals were monitored three times daily for signs of diarrhea, dehydration, appetite and water consumption. Rectal swabs from each ferret were cultured for C. jejuni by direct plating on C. jejuni selective agar. At the appropriate time, blood samples were obtained by bleeding the animals from the jugular vein while under light anesthesia using acepromazine-ketamine. Collected sera were assayed for specific anti-Campylobacter immunoglobulin levels. At the conclusion of each experiment, animals were lightly anaesthetized with acepromazine-ketamine then euthanized by intracardiac injection of sodium pentobarbital (Burr et al., 2005).
• Challenge Protocol: Food was withheld prior to challenge. Animals received ketamine plus acepromazine i.m. Following sedation, the vaccine or challenge dose was administered orally. Animals being fed live organisms were administered paragoric i.p. For secondary challenge the procedure was otherwise identical, except that NaHCO3 was delivered prior to challenge. In addition, drinking water was supplemented with tetracycline prior to rechallenge. All challenge doses were monitored by plate counts (Burr et al., 2005).
• Efficacy: Ferrets show some conservation of protection against disease induced by Campylobacter. Upon rechallenge, homologous protection was 67-84%. Heterologous challenge resulted in 67-80% protection. These data indicate that the strain chosen for use in humans protects against disease caused by two of the major serotypes responsible for human disease (Burr et al., 2005).
• Description: The strong IgG responses seen upon rechallenge of vaccinated or previously challenged animals may not be protective in themselves but could indicate the magnitude of other unmeasured antibody responses following immunization. Whatever the exact nature of the protective immune responses associated with the CWC vaccine, it is clear that the vaccine offers protection which may be relatively conserved among clinically important serotypes of Campylobacter (Burr et al., 2005).